SUNN Study • PLOS ONECommunity Elastography
Section 5 • Citizen Science & Early Detection

Why Proactive Screening Saves Lives: The SUNN Study & Patient Webinars

When our SUNN study brought mobile FibroScan screening directly into Texas neighborhoods, 57% of asymptomatic adults had hidden steatosis and 16% already showed silent fibrosis risk — proving why 'watchful waiting' must end.

Editor's Note: Registered on ClinicalTrials.gov as NCT03726827 (Screening for Undiagnosed NAFLD and NASH — SUNN) and published in PLOS ONE before the 2023 nomenclature update, the SUNN study remains one of the clearest real-world demonstrations of undiagnosed MASLD and at-risk MASH in everyday American communities.
Straight Talk From a Fellow Patient

For years, medical committees argued against screening asymptomatic adults for steatotic liver disease because they assumed primary care blood tests would catch serious cases — and because approved drugs didn't exist yet. As patients who landed in stage F4 cirrhosis with 'normal' routine checkups, we knew that assumption was costing lives.

So we put a FibroScan machine directly into community venues across South Houston and Galveston County and scanned over a thousand everyday volunteers who had zero known history of liver disease. Finding steatosis in 57% and combined steatosis-plus-fibrosis signals in 16% changed the conversation permanently.

Infographic comparing high prevalence of MASLD and MASH against low diagnosis awareness rates
Why Waiting for Symptoms Fails: Community FibroScan screening consistently uncovers steatosis and silent fibrosis in everyday adults whose routine blood panels never raised an alarm.

1. Why We Built a Mobile Community Screening Trial (The Story Behind SUNN)

If you want to understand why millions of Americans still learn they have advanced liver scarring by total surprise, look back at the medical catch-22 we faced in 2018. At the time, national guideline panels hesitated to endorse proactive liver screening for symptom-free adults with diabetes or obesity (when MASLD and MASH were formerly called NAFLD and NASH). Their reasoning ran in a circle: primary care doctors relied on routine ALT and AST enzymes that missed half of real disease, needle biopsies were too invasive and risky for broad screening, and FDA-approved MASH medications hadn't crossed the finish line yet.

From a patient's chair, that logic was backward and deadly. You don't need a prescription pill to benefit from knowing your liver is silently scarring at Stage F2 — food swaps, daily walking, ditching sugary drinks, cutting out alcohol, and optimizing diabetes and statin care already reverse early injury when people are told the truth in time. Partnering with hepatologist Dr. John M. Vierling (Baylor College of Medicine) and colleagues, our patient foundation took portable FibroScan elastography out of academic hospital towers and rolled it straight into neighborhood health fairs, churches, community centers, and local clinics across South Houston and Galveston County, Texas.

2. Landmark Proof: Peer-Reviewed Results From the SUNN Study (NCT03726827)

SUNN Study MetricPeer-Reviewed Finding (Eskridge et al., PLOS ONE 2021)What It Means for You & Your Doctor
Who Walked In?1,070 self-selected, asymptomatic community adults in South Houston & Galveston County with zero prior known liver disease; 940 met full eligibility and technical scan criteria for final statistical analysis.These were not hospitalized liver patients — they were everyday neighbors running errands who felt fine and had never been warned by a routine checkup.
Community Diversity67% women (n = 626) and 33% men; ~62% Hispanic (n = 581), 15% African American, 14% Caucasian, and 4% Asian.When painless, free point-of-care screening comes directly into underserved and high-risk neighborhoods, families show up eagerly to learn their numbers.
Undiagnosed Liver Fat (MASLD)57% of analyzed participants demonstrated hepatic steatosis (elevated CAP dB/m) without elevated fibrosis stiffness.Catching MASLD in this early steatosis window gives you years of runway to clear liver fat with Mediterranean food, coffee, and movement before scarring starts.
Silent Steatosis + Fibrosis Signals (At-Risk MASH)16% — roughly 1 in 6 symptom-free community volunteers — already showed both steatosis and elevated liver stiffness (kPa) pointing toward silent MASH fibrosis (73% combined steatosis or MASH signal overall)."Watchful waiting" leaves 1 in 6 everyday community adults walking around with silent fibrotic liver injury that routine symptom checks miss completely.
Quantified Weight & BMI RiskCompared with normal-weight participants, overweight adults carried 2.47× higher odds (p = 0.026) and adults with obesity faced 9.61× higher odds (p < 0.001) of fibrosis stage F1 or greater.Visceral metabolic stress powerfully accelerates collagen scarring — yet modest, sustained 7%–10% weight loss reverses that exact pressure.
Diabetes, Blood Pressure & Lifestyle ProtectorsLiving with diabetes raised proxy MASH odds 2.41× (p = 0.003) and hypertension raised odds 2.21× (p = 0.008), while regular exercise and healthier eating habits were statistically protective.If you live with Type 2 diabetes, prediabetes, hypertension, or belly weight, request a FIB-4 score and elastography check now — never wait for high ALT/AST.

3. How Community Evidence Helped Drive Today's Two-Tier Screening Guidelines

Published in PLOS ONE in November 2021, the SUNN study added hard real-world numbers to a growing international chorus demanding an end to passive liver care. Between 2023 and 2026, the American Diabetes Association (ADA), AASLD, EASL, and AGA overhauled their clinical pathways (Clinical Guidelines Hub). Today, medical societies no longer tell doctors to wait for symptoms or elevated liver enzymes in high-risk adults. Instead, they endorse a fast, practical two-tier screening pathway right inside primary care and diabetes clinics:

Tier 1: Automatic Blood FIB-4 Check (Zero Extra Lab Draw)

Every adult with Type 2 diabetes, prediabetes, obesity plus cardiometabolic risk factors, or steatosis spotted on any imaging scan gets a FIB-4 calculation from routine age, AST, ALT, and platelet labs. If FIB-4 is below 1.3 (under age 65), advanced fibrosis is unlikely and your primary care clinician simply rechecks FIB-4 every 1 to 2 years while supporting metabolic health.

Tier 2: Elastography (FibroScan) or ELF Blood Confirmation

Whenever FIB-4 lands at 1.3 or higher (or ≥2.0 in adults 65+), guidelines call for a second-line stiffness check using VCTE / FibroScan or the Enhanced Liver Fibrosis (ELF) blood test. Stiffness below 8.0 kPa stays safely in primary care; 8.0 kPa or higher flags at-risk MASH fibrosis for specialist care and potential FDA-approved MASH therapy.

4. What to Expect at a Community Liver Screening Event (and What to Do With Your Numbers Next)

Mobile FibroScan vans, health-fair liver booths, and pharmacy or clinic screening days are popping up in more cities every year. If you've never had transient elastography before, here is how to make sure your 10-minute scan is accurate — and how to turn a screening handout into smart medical follow-up:

Before: Fast Lightly for 3 Hours

Skip food and sugary or milky drinks for at least 3 hours before your scan (plain water is fine). Digestion sends a surge of portal blood into the liver right after a meal, which temporarily swells the organ and can falsely inflate your kPa stiffness score by 1 to 3 points.

During: 10 Painless Pulses

You keep your everyday clothes on, lie flat on an exam table with your right arm resting behind your head, and lift just a few inches of your shirt over your lower right ribs. A water-based gel probe sends 10 quick mechanical flicks — zero needles, zero radiation, and done in under 10 minutes.

After: Photograph Both Numbers

Ask for the printed slip or snap a clear phone photo before leaving. Make sure you capture CAP (dB/m) for fat, median stiffness (kPa) for scarring, probe size (M or XL), and the IQR/med % quality check (ideally ≤30%).

Typical Community Screening ResultPlain-Language MeaningYour Exact Next Step
CAP <248 dB/m & Stiffness <8.0 kPaLow liver fat and soft, flexible liver tissue today.Save the slip in your health folder as a baseline. If you have diabetes or metabolic syndrome traits, still recheck blood FIB-4 every 1–2 years at routine physicals.
Elevated CAP (≥248–280+ dB/m) with Stiffness <8.0 kPaElevated liver fat (steatosis / early MASLD window) without substantial scarring signals.Your golden prevention window: share the printout with your PCP, optimize A1c, blood pressure, and lipids, ditch liquid sugars, and start our Simplest Day-One Diet Swaps.
Intermediate Stiffness (8.0–11.9 kPa)Possible Stage F2–F3 fibrotic MASH — warrants formal clinical confirmation.Book a dedicated primary care or GI/hepatology visit. Bring fasting labs, calculate FIB-4/ELF, rule out secondary liver causes, and ask whether you qualify for approved MASH therapies or a trial.
Higher Stiffness (≥12.0 kPa)Possible advanced F3 bridging fibrosis or F4 cirrhosis (though recent meals, probe sizing, or acute inflammation can overestimate kPa).Stay calm, stop all alcohol and NSAID painkillers immediately, and request a prompt hepatologist referral for confirmatory staging, platelet check, and ultrasound review. See Understanding MASH Cirrhosis.

5. From Screening Research to Ongoing SLF Patient Programs

Wellness & LIVER Webinar Series

Our multi-part LIVER (Live Interactive Virtual Education and Review) and Wellness Webinar programs bring hepatologists, dietitians, and patient panelists together to answer unscripted questions on noninvasive testing, vaccines, clinical trials, and living well with MASLD/MASH. Watch recorded sessions anytime in our MASLD & MASH Video Library.

Join Active Patient Citizen-Science Today

Help us close the diagnostic gap nationwide: share your care journey in the State of Steatotic Care Survey, build sustainable habits through The Wellness League, or sign up free at SteatoticLiver.org/join for upcoming screening alerts and live Q&As.

Common Questions Patients & Families Ask

Does a community FibroScan hurt, involve needles or radiation, or require me to undress?

None of those. A FibroScan uses harmless ultrasound shear waves — zero needles, zero X-ray radiation, and zero enclosed MRI tunnels. You stay in your street clothes and simply lift a few inches of your shirt on your right side while lying on an exam table. Each of the 10 quick readings feels like a light finger tap against your ribs, and the whole check finishes in about 8 to 10 minutes.

What if my community FibroScan stiffness (kPa) came back high right after I ate lunch?

Don't panic — and definitely tell your doctor when you last ate before the scan. Eating a meal within 3 hours boosts portal vein blood flow into the liver, temporarily tightening the organ and pushing kPa readings higher than your true fasting baseline. High liver enzymes from a temporary viral illness, right-sided heart congestion, or using a standard M probe when an XL probe was needed can also overestimate stiffness. Your clinician will repeat a proper 3-hour-fasting scan alongside blood FIB-4 or ELF testing to confirm your real stage.

Why can't a mobile screening booth hand me a final medical diagnosis or prescription on the spot?

Elastography measures physical liver fat attenuation (CAP) and tissue stiffness (kPa), which makes it a superb early-warning radar — yet a full clinical diagnosis requires a physician or advanced practice clinician to review your complete blood panel, check alcohol and medication history, and rule out other causes of liver inflammation (such as viral hepatitis B or C, iron overload, or autoimmune liver disease). Think of your screening printout as the ticket that gets your primary care visit focused on the right follow-up.

How do I watch recorded LIVER and Wellness Webinars or get notified before the next live Q&A?

All four core parts of our LIVER interactive patient and research webinar series are available free on demand in our MASLD & MASH Video Library, and signing up free at SteatoticLiver.org/join puts you on our email alert list for upcoming live webcasts, Care Survey reports, and regional screening initiatives.

Take Charge of Your Liver Health With the Steatotic Liver CommunityMembership is free. Get plain-spoken updates on MASLD & MASH treatments, live screening calculators, and patient advocacy.